• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Traws Pharma Inc.

    10/8/25 4:19:30 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRAW alert in real time by email
    DEFA14A 1 tm2527912d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

    (Amendment No.   )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    TRAWS PHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

     

    NOT APPLICABLE

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! TRAWS PHARMA, INC. 12 PENNS TRAIL NEWTOWN, PA 18940 TRAWS PHARMA, INC. 2025 Annual Meeting Vote by November 20, 2025 11:59 PM ET You invested in TRAWS PHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on November 21, 2025. Vote Virtually at the Meeting* November 21, 2025 9:00 AM, EDT Virtually at: www.virtualshareholdermeeting.com/TRAW2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V80481-P39521 Get informed before you vote View the Notice & Proxy Statement, Annual Report on Form 10-K and Amendment No. 1 to Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to November 7, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V80482-P39521 1. Election of Directors For Nominees: 01) Iain Dukes, D. Phil. 02) Werner Cautreels, Ph.D. 03) Trafford Clarke, Ph.D. 04) John Leaman 05) Nikolay Savchuk, Ph.D. 06) M. Teresa Shoemaker 07) Jack E. Stover 2. To consider and vote upon the amendment and restatement of our 2021 Incentive Compensation Plan, as amended and restated. For 3. To approve, on an advisory basis, the compensation of our named executive officers. For 4. To approve, on a non-binding advisory basis, the frequency of holding an advisory vote to approve the compensation of our named executive officers. 2 Years 5. Ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 6. To approve the adjournment of the Annual Meeting to another place, or later date or dates, if necessary or appropriate, to solicit additional proxies in the event that we have not received sufficient votes in favor of any of the foregoing proposals. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $TRAW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRAW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRAW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

    NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws' Board of Directors (the "Board") has eliminated the interim notation of its key executives Iain Dukes and Charles Parker, who are now Chief Executive Officer and Chief Financial Officer, respectively. "Dr. Leaman brings more than a decade of experience in finance, M&A and

    10/6/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

    Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficacy in PAXLOVID®-ineligible subjects, who represent a significant vulnerable population with few available treatment options Top-line data from both trials expected by year-end 2025 NEWTOWN, Pa., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory vira

    8/18/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Clarke Trafford

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    6/23/25 5:59:03 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stover Jack E

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    6/23/25 5:54:01 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Shoemaker Mary Teresa

    4 - Traws Pharma, Inc. (0001130598) (Issuer)

    6/23/25 5:52:01 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    SEC Filings

    View All

    SEC Form DEFA14A filed by Traws Pharma Inc.

    DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)

    10/8/25 4:19:30 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Traws Pharma Inc.

    DEF 14A - Traws Pharma, Inc. (0001130598) (Filer)

    10/8/25 4:16:02 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Traws Pharma, Inc. (0001130598) (Filer)

    10/6/25 7:00:39 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Leadership Updates

    Live Leadership Updates

    View All

    Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

    NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws' Board of Directors (the "Board") has eliminated the interim notation of its key executives Iain Dukes and Charles Parker, who are now Chief Executive Officer and Chief Financial Officer, respectively. "Dr. Leaman brings more than a decade of experience in finance, M&A and

    10/6/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Announces Management Updates

    Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

    3/28/25 4:30:00 PM ET
    $IKNA
    $IOVA
    $TRAW
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $TRAW
    Financials

    Live finance-specific insights

    View All

    Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

    Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoing infection risk and greater need, with waning vaccine utilization A submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir in newly diagnosed COVID patients, with extensions to assess rebound and Long COVID, as well as evaluation in PAXLOVID®-ineligible subjects TXM program to emphasize focus on stockpiling readiness Traws to host a Q2 2025 business upda

    8/14/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

    NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress. Conference Call and Webcast Information Date: Thursday, August 14, 2025, at 8:30 AM ETParticipant Dial-in (U.S.): 1-877-407-0789Participant Dial-in (International): 1-201-689-8562Conference ID: 13754425Webcast Access: Cl

    8/8/25 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

    Merger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond Lead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in the Phase 1 dose extension study in AustraliaCOVID-19 program, ratutrelvir, completed the Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) study in Australia Oncology strategy includes investigator-sponsored trials (ISTs), planned to begin in H2 2024, adding a new

    8/15/24 7:00:00 AM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRAW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Traws Pharma Inc.

    SC 13D/A - Traws Pharma, Inc. (0001130598) (Subject)

    11/6/24 4:12:57 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Traws Pharma Inc.

    SC 13D - Traws Pharma, Inc. (0001130598) (Subject)

    9/23/24 6:44:56 PM ET
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care